Fundz

Alchemab Raises £60M ($82M) In Series A Financing To Advance Novel Platform For Identifying Disease-Modifying Antibody Therapeutics

PRIVATEApr 15, 2021

Amount Raised

€60

Round Type

Series A

LondonBiotechnologyHealth CareTherapeuticsPharmaceutical

Description

Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.

Who else raised in Therapeutics and Pharmaceutical around the same time

Companies in the same sectors as Alchemab Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Nuvalent raised $135M on May 12, 2021.
  • Nuvalent raised $135M (Series B) on May 11, 2021.
  • RxMP Therapeutics raised $1M (Seed) on April 21, 2021.
  • Os Therapies raised $6M (Series A) on April 20, 2021.
  • Liquidia raised $22M on April 16, 2021.
  • CUREMARK LLC raised $1.5M (Seed) on April 14, 2021.

Who to call at Alchemab Therapeutics, and when

A new round usually means Alchemab Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Alchemab Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Alchemab Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Alchemab Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Alchemab Therapeutics

Location

London, England, United Kingdom

About

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Alchemab Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

5 contacts
Verified contactsJorge D., Director Antibody Discovery hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Alchemab Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Alchemab Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.